Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...

TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S. ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancerZEJULA is the only PARP inhibitor that has demonstrated a clinically...

Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO NATIONAL HARBOR, Md., March 13, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of secondary endpoint results...

Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer WALTHAM, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the opening of an expanded access program (EAP) in the...